In an era where fertility science intersects with genomics, hopeful parents now have access to tools that were once unimaginable. Among the most transformative is Preimplantation Genetic Testing (PGT), a sophisticated advancement in assisted reproduction that is redefining how embryos are selected during IVF. With increasing focus on not just achieving pregnancy, but ensuring healthy, full-term outcomes, this technology is opening new pathways for families seeking precision, reassurance, and results. Leading this revolution is Dr. Hrishikesh Pai, one of the most trusted names in fertility care, whose expertise and pioneering role in introducing genetic screening to India have helped countless couples realize their dream of parenthood.
As a reputed IVF doctor in Mumbai, India, Dr. Hrishikesh Pai has spent over four decades at the forefront of reproductive medicine. His ability to integrate cutting-edge science with individualized treatment strategies has placed Bloom IVF—his nationwide network of 11 world-class fertility centers—among the most advanced in the country. At Bloom IVF, Preimplantation Genetic Testing, especially PGT-A (for chromosomal abnormalities) and PGT-M (for single-gene disorders), is now standard practice in many high-risk or complex IVF cases. “With PGT, we’re no longer just transferring embryos—we’re transferring knowledge, confidence, and precision into each cycle,” says Dr. Pai. “It’s about helping patients make the most informed choices in a deeply personal journey.”
PGT-A, or Preimplantation Genetic Testing for Aneuploidy, is designed to assess embryos for abnormal numbers of chromosomes, a key cause of failed implantation, miscarriages, and developmental disorders like Down syndrome. Even embryos that appear morphologically normal may carry chromosomal anomalies, particularly in older women or those with a history of repeated IVF failures. “Age-related decline in egg quality is one of the major causes of chromosomal errors in embryos,” Dr. Pai explains. “With PGT-A, we can identify euploid embryos—those with the correct number of chromosomes—and prioritize them for transfer. This directly translates into higher implantation rates and reduced miscarriage risk.”
PGT-M, or testing for monogenic diseases, provides an additional layer of safety for families who may be carriers of inherited conditions such as thalassemia, cystic fibrosis, Tay-Sachs disease, or sickle cell anemia. Through this test, embryos are screened for specific genetic mutations before implantation, allowing parents to avoid passing on serious illnesses to their future children. “This is not just about pregnancy—it’s about delivering a healthy child who can thrive,” Dr. Pai affirms. “For carrier couples or those with a family history of genetic disorders, PGT-M is a life-altering tool.”
Dr. Pai’s dedication to evidence-based innovation has yielded real-world success stories. One recent case involved a 39-year-old woman who had experienced three miscarriages following IVF cycles at other clinics. Suspecting chromosomal abnormalities, Dr. Pai’s team performed IVF with PGT-A. Of the eight embryos biopsied, only two were found to be chromosomally normal. A single euploid embryo was transferred, and the patient delivered a healthy baby girl at full term. “It’s a classic example of how one good embryo—identified through precision testing—can make all the difference,” Dr. Pai notes.
Another case involved a young couple, both carriers of beta-thalassemia, who had lost a child to the condition. The emotional trauma they endured made them hesitant about future pregnancies. Through IVF with PGT-M, Dr. Pai’s lab identified and excluded embryos carrying the disease. The couple now has a healthy child, free from thalassemia. “This is the power of genetic medicine—prevention at its most compassionate,” Dr. Pai shares.
The benefits of PGT extend beyond diagnosis. By transferring a single, chromosomally normal embryo, doctors can avoid the risks associated with multiple pregnancies while maintaining high success rates. This aligns with international best practices and supports safer maternal outcomes. Additionally, PGT-guided IVF cycles help reduce emotional and financial strain by lowering the number of failed attempts and enhancing predictability. “In many cases, the first cycle is the last cycle needed,” says Dr. Pai.
Bloom IVF’s success rates reflect this commitment to scientific precision. With IVF success rates between 40–50% per cycle—and even higher when PGT is utilized—patients are increasingly empowered to pursue treatment with hope and clarity. Dr. Pai’s contributions to India’s reproductive landscape have been recognized globally, earning him accolades such as the ISAR Lifetime Achievement Award, the FRCOG from the UK, and the ET Healthworld IVF Legend Award. Yet, he remains grounded in one guiding principle: personalized care built on science and empathy.
“Our goal is to take the guesswork out of IVF,” Dr. Pai emphasizes. “By combining deep genetic insight with world-class embryology and patient-first protocols, we’re helping couples make family planning decisions that are both intelligent and emotionally secure.”
As fertility treatments evolve, so too does the opportunity for families to make choices that align with their values, health goals, and dreams. Thanks to pioneers like Dr. Hrishikesh Pai, the promise of genetically sound, high-success IVF is no longer a hope for the future—it’s a reality today.
For consultations and expert fertility care:
Dr. Hrishikesh Pai
Bloom IVF Group, Lilavati Hospital, Bandra (W), Mumbai
https://drhrishikeshpai.com
About Dr. Hrishikesh Pai:
Dr. Hrishikesh Pai is one of India’s most accomplished IVF specialists, with over 40 years of experience in reproductive medicine. As the Founder and Medical Director of Bloom IVF Group, he has pioneered several fertility innovations in India, including IMSI, oocyte freezing, PGT, and assisted laser hatching. Known for his high success rates and compassionate care, Dr. Pai continues to transform the lives of couples facing infertility through his evidence-based, personalized approach.
